Alzheimer disease (AD) is a progressive cognitive disorder leading to dementia
1 in which the brain gradually accumulates both amyloid-β (Aβ) and tau pathologies.
2 Autopsy studies identified the early stages of Aβ and tau pathologies in individuals who were clinically normal during life, representing a preclinical stage of AD.
3 Based on autopsy studies,
4 the prevailing research hypothesis posits that Aβ precedes and accelerates neocortical tau pathology, which together precipitate cognitive decline. Molecular positron emission tomography (PET) tracers for Aβ
5 and tau
6 have made it possible to detect these pathologies in living individuals, including in clinically normal adults. However, previous longitudinal PET studies tracked either Aβ
7,8 or tau
9,10 accumulation; to our knowledge, a temporal sequence of Aβ and tau accumulation has not yet been evaluated. To observe the sequence of these pathologic events, we investigated the trajectories and temporal courses of longitudinal Aβ-PET and longitudinal tau-PET data. Improved understanding of these trajectories is needed to efficiently test therapeutic strategies designed to halt the progression of pathology and delay cognitive decline. While cognitive decline has been demonstrated in longitudinal studies of older adults with elevated levels of Aβ pathology at baseline,
7,11-13 tau-PET may be more closely linked to neuronal injury and cognition.
14-16 We therefore conducted a prospective natural history study to determine whether serial Aβ and tau measures were associated with concurrent and subsequent, serial measures of cognitive performance.